At the iwNHL 2014, Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Wolfram Brugger (University of Freiburg, Villingen-Schwenningen, Germany) and Dr Myron Czuczman (Roswell Park Cancer Institute, New York, USA) about the current and future clinical application of targeted or chemotherapy-free therapies in lymphoma. They discuss their experiences and some of the challenges of these therapies in clinical practice. It is emphasised that targeted therapies should not necessarily be used as standalone approaches. Combinations of targeted therapies and conventional therapies should be considered, and emerging clinical trials investigating combinations are described. The use of patient’s age to determine therapeutic approach may not be appropriate; it is important to find the right therapy for individual patients.
Related Videos In Lymphoma
John Kuruvilla, ASCO20: Results of the KEYNOTE-204 Phase III Trial in Patients with cHL
John Kuruvilla joins us to discuss the presentation a the ASCO20 Virtual Meeting of the results of the KEYNOTE-204 trial, the first positive phase III trial of an anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma. Questions 1. What are the unmet needs in the treatment of classical Hodgkin lymphoma? (0:06) 2. […]
Theodoros P Vassilakopoulos, MD, PhD, EHA 2019 – Exciting new developments in Hodgkin lymphoma
At the EHA conference in Amsterdam we are joined by Professor Theodoros P Vassilakopoulos to discuss the most exciting new developments in standards of care for Hodgkin lymphoma. Questions 1. What are the limitations of current standards of care for Hodgkin lymphoma (HL)? (0:05) 2. What is the role of brentuximab vedotin in the current […]
Andrea Gallamini, EHA 2019 – Three-year Update of the ECHELON-1 Study
We are joined by Andrea Gallamini, at EHA 2019 to discuss his presentation on frontline brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Questions 1. Could you tell us a little about the ECHELON-1 study and its findings? (0:05) 2. What have we learned from the 3-year […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!